Pathogenesis from Inflammation to Cancer in NASH-Derived HCC

Pathogenesis from Inflammation to Cancer in NASH-Derived HCC

Simiao Yu,1,&ast; Jingxiao Wang,2,&ast; Haocheng Zheng,3,&ast; Ruilin Wang,4,&ast; Nadia Johnson,1 Tao Li,3 Ping Li,1 Jie Lin,5 Yuan Li,5 Jin Yan,6 Ying Zhang,6 Zhenyu Zhu,6 Xia Ding3,7 1Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, People’s Republic o...

Full description

Bibliographic Details
Main Authors:	Yu S, Wang J, Zheng H, Wang R, Johnson N, Li T, Li P, Lin J, Li Y, Yan J, Zhang Y, Zhu Z, Ding X
Format:	Article
Language:	English
Published:	Dove Medical Press 2022-08-01
Series:	Journal of Hepatocellular Carcinoma
Subjects:	non-alcoholic steatohepatitis hepatocellular carcinoma inflammation to cancer transition metabolic dysregulation immune microenvironment.
Online Access:	https://www.dovepress.com/pathogenesis-from-inflammation-to-cancer-in-nash-derived-hcc-peer-reviewed-fulltext-article-JHC

Similar Items

The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products
by: Gaoxuan Shao, et al.
Published: (2022-07-01)

Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies
by: Jorge Gutiérrez-Cuevas, et al.
Published: (2022-12-01)

Higher Risk of Tumor Recurrence in NASH-Related Hepatocellular Carcinoma Following Curative Resection
by: Shih-Chieh Chien, et al.
Published: (2022-10-01)

Current and Potential Therapies Targeting Inflammation in NASH
by: Somaya Albhaisi, et al.
Published: (2021-12-01)

Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western DietSummary
by: Souradipta Ganguly, et al.
Published: (2021-01-01)

Suppression of NASH-Related HCC by Farnesyltransferase Inhibitor through Inhibition of Inflammation and Hypoxia-Inducible Factor-1α Expression
by: Kohei Yamada, et al.
Published: (2023-07-01)

Downregulation of 15-PGDH enhances MASH-HCC development via fatty acid-induced T-cell exhaustion
by: Xichen Hu, et al.
Published: (2023-12-01)

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
by: Hyunmi Kim, et al.
Published: (2021-04-01)

Hepatocellular loss of mTOR aggravates tumor burden in nonalcoholic steatohepatitis-related HCC
by: Andreas Kroh, et al.
Published: (2023-12-01)

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
by: Ryan D. Welch, et al.
Published: (2022-03-01)

Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma
by: Daryl Ramai, et al.
Published: (2021-02-01)

Tumorigenesis from non-alcoholic steatohepatitis to hepatocellular carcinoma
by: Yu Junjie, et al.
Published: (2023-01-01)

Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis
by: Kanehiko Suwa, et al.
Published: (2020-01-01)

State of CD8+ T cells in progression from nonalcoholic steatohepatitis to hepatocellular carcinoma: From pathogenesis to immunotherapy
by: Xin Zhong, et al.
Published: (2023-09-01)

Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC)
by: Jingquan Huang, et al.
Published: (2023-11-01)

Establishment of Novel Mouse Model of Dietary NASH Rapidly Progressing into Liver Cirrhosis and Tumors
by: Qianqian Zheng, et al.
Published: (2023-07-01)

Prevalence of Non Alcoholic Fatty Liver Disease and its Association with Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus
by: Zahra Heidari, et al.
Published: (2017-05-01)

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors
by: Yoshihisa Takahashi, et al.
Published: (2023-10-01)

Restoration of CD4<sup>+</sup> T Cells during NAFLD without Modulation of the Hepatic Immunological Pattern Is Not Sufficient to Prevent HCC
by: Madison Isbell, et al.
Published: (2022-11-01)

REVIEW PAPER<br>Non-alcoholic steatohepatitis (NASH)
by: János Fehér, et al.
Published: (2005-04-01)

Rosavin Ameliorates Hepatic Inflammation and Fibrosis in the NASH Rat Model via Targeting Hepatic Cell Death
by: Reda Albadawy, et al.
Published: (2022-09-01)

Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
by: Cristina Piras, et al.
Published: (2021-10-01)

Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH
by: Hegazy MA, et al.
Published: (2020-10-01)

HCV and HCC Tango—Deciphering the Intricate Dance of Disease: A Review Article
by: Ivana Milosevic, et al.
Published: (2023-11-01)

The Role of RECK in Hepatobiliary Neoplasia Reveals Its Therapeutic Potential in NASH
by: Ryan J. Dashek, et al.
Published: (2021-10-01)

Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research
by: Clarissa Berardo, et al.
Published: (2020-12-01)

NAFLD-Related HCC: Focus on the Latest Relevant Preclinical Models
by: Jing Fang, et al.
Published: (2023-07-01)

Advances and Challenges in Hepatocellular Carcinoma: A Comprehensive Review
by: Mateusz Dorochowicz, et al.
Published: (2023-12-01)

Dipeptidyl peptidase IV (DDP IV) in NASH patients
by: Yasemin H. Balaban, et al.
Published: (2007-10-01)

Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression
by: Maria Kotsari, et al.
Published: (2023-07-01)

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice
by: Jia Xu, et al.
Published: (2022-05-01)

The effect of chronic intermittent hypoxia in the evolution of NASH
by: Amal Abd El-Azeem I., et al.
Published: (2012-07-01)

MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges
by: Anju G. S. Phoolchund, et al.
Published: (2024-01-01)

Relevance of the NLRP3 Inflammasome in the Pathogenesis of Chronic Liver Disease
by: Xiaoqin Wu, et al.
Published: (2017-12-01)

New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?
by: Arshi Khanam, et al.
Published: (2022-12-01)

Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor
by: Nouf Aljobaily, et al.
Published: (2022-12-01)

Advances in the Pathogenesis of Metabolic Liver Disease-Related Hepatocellular Carcinoma
by: Chen P, et al.
Published: (2024-03-01)

Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis
by: Eman A. Ahmed, et al.
Published: (2022-12-01)

S-adenosylmethionine metabolism and liver disease
by: José M. Mato, et al.
Published: (2013-03-01)

A study of 3013 cases of hepatocellular carcinoma: Etiology and therapy before and during the current decade
by: Miao‐Shan Lim, et al.
Published: (2021-09-01)